Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT04290273
Other study ID # 2-004-20
Secondary ID
Status Withdrawn
Phase N/A
First received
Last updated
Start date September 2024
Est. completion date November 2024

Study information

Verified date March 2024
Source University of Dundee
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Erythema is a physiological response to an insult on the skin. One such insult is ultraviolet (UV) radiation, with the resultant erythema also known as sunburn. It is a reddening of the skin as a result of increased blood flow to the area. By controlled exposure to UV radiation, a minimal erythema dose (MED) indicative of threshold erythemal sensitivity to the exposure waveband may be determined - this is determined visually by a trained clinician as the dose of light required to cause a just perceptible reddening of the skin. The MED of a specific patient on a specific skin site is an important measurement - it can allow for determination of initial dose in UV phototherapy, provides an indication of background levels of photosensitivity in diagnostic phototesting and may be influenced by exogenous factors, such as photoactive drugs. The erythema response has been measured previously using non-invasive hand-held devices for a variety of UV exposures, including narrow-band (NB-)UVB, UVA and UVA1. Typically, the participant will be exposed in the morning (t = 0h) and have a reading taken immediately after. These readings are assessed visually by a trained clinician, or occasionally reflectance devices are used quantify erythema. The participant will then return at the end of the working day (t ~ 8h) for another reading, and again the next morning for another reading (t ~ 24h). This results in large gaps in the knowledge of erythemal response over time. In this study the investigators aim to characterise the erythema response as a result of UV insult using a wearable erythema device to take continual measurements. This would allow us to more accurately determine the time point of peak erythema, which would inform and potentially change our current practice in reading MEDs. The investigators have previous experience of studies using reflectance devices to measure erythema time course at fixed intervals, however there are still gaps in the knowledge of the time course response of erythema. There is no expected health benefit to participants in this study, however they may gain a better understanding of their responses to ultraviolet light MED testing. Controlled UV exposures are commonplace in our practice in the Photobiology Unit and it is not foreseen that there are any risks to participation in the study. The primary objective in this study is to determine when the peak erythema index occurs in a healthy volunteer group. Success of this outcome will help fill in these gaps in the knowledge about the time course of erythema. The secondary objective is to determine if there is any difference in MED and/or peak erythema if the UV exposure is delivered in the morning vs. the afternoon. The outcomes of the research will be 20 sets (2 per participant) of continuous 48-hour erythema measurements.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date November 2024
Est. primary completion date November 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Healthy volunteers. No clinically significant abnormality identified by evaluation of medical history, in particular no evidence of photosensitivity - Adult males and females, >18 years only - Capable of giving informed consent - Able to understand and adhere to protocol requirements - Skin phototype I - III Exclusion Criteria: - Contact allergy to adhesives tapes - Abnormal rash/pigmentation on thighs - Unable to give informed consent - Known to have a light sensitive disorder - Pregnant, breastfeeding or planning to conceive - Skin phototype IV - VI - Lack of space on thighs for test procedures

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
MED Test
Participant is irradiated with several doses of UV light on small areas of the outer thigh. 24 hours later this area is visually inspected for erythema, and the minimal erythemal dose (MED) is determined.
Device:
Wearing device
Participants wear a portable erythema measurement device for 48 hours. The device shines light on the skin at frequent intervals and measures skin 'redness'. The device is removed by a technician after the 48 hours.

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
University of Dundee NHS Tayside

References & Publications (3)

Dolotov LE, Sinichkin YP, Tuchin VV, Utz SR, Altshuler GB, Yaroslavsky IV. Design and evaluation of a novel portable erythema-melanin-meter. Lasers Surg Med. 2004;34(2):127-35. doi: 10.1002/lsm.10233. — View Citation

Man I, Dawe RS, Ferguson J, Ibbotson SH. An intraindividual study of the characteristics of erythema induced by bath and oral methoxsalen photochemotherapy and narrowband ultraviolet B. Photochem Photobiol. 2003 Jul;78(1):55-60. doi: 10.1562/0031-8655(2003)0782.0.co;2. — View Citation

Man I, McKinlay J, Dawe RS, Ferguson J, Ibbotson SH. An intraindividual comparative study of psoralen-UVA erythema induced by bath 8-methoxypsoralen and 4, 5', 8-trimethylpsoralen. J Am Acad Dermatol. 2003 Jul;49(1):59-64. doi: 10.1067/mjd.2003.419. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Measure 2x 48 hour erythema time courses on each participant 6 months
Secondary Measure 2 MEDs (minimal erythemal doses) in each participant, at morning and afternoon exposures each 6 months
See also
  Status Clinical Trial Phase
Completed NCT01659853 - Efficacy and Safety Study Comparing CD07805/47 Gel 0.5% to Azelaic Acid Gel 15% in Subjects With Erythema of Rosacea Phase 3
Completed NCT00839462 - Efficacy of Dexpanthenol in Thermic Erythema Phase 2
Not yet recruiting NCT06016361 - Evaluation of a Novel Amino Acid Based Moisturizing Cream as Part of the Daily Standard Skincare Regimen Recommended During Radiation Therapy N/A
Completed NCT03633877 - Durapore vs. Hy-Tape to Secure The Endotracheal Tube N/A
Active, not recruiting NCT02876107 - Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer Phase 2
Completed NCT06369675 - Skin Irritation Potential of MOB015B in Healthy Subjects Using a Cumulative Irritant Patch Test Design Phase 1
Completed NCT03352323 - An Evaluation of the Reduction in Erythema in Adult Patients With Moderate to Severe Persistent Facial Erythema Associated With Rosacea Phase 3
Completed NCT06369727 - Study to Evaluate the Sensitizing Potential of MOB015B in Healthy Subjects Using a Repeat Insult Patch Test Design Phase 1
Completed NCT03041064 - Multiday Beach Study N/A
Completed NCT02832141 - Effect of Thoracic Spine Mobilization on Sympathetic Nervous Systems
Completed NCT02131636 - Efficacy and Safety of AGN-199201 in Patients With Persistent Erythema Associated With Rosacea Phase 3
Completed NCT01636765 - Study of Inter- and Intra-rater Reliability of the Clinician Erythema Assessment Scale
Terminated NCT01597921 - A DB Randomized Study of R1 and R2 WaterJel / AloeVera Jell in Prevention of Radiation Dermatitis in Breast Cancer N/A
Completed NCT01124513 - Melanin Index in Those With Fitzpatrick Skin Phototypes I-VI N/A
Terminated NCT03496584 - Effects of Phytonutrients on Vascular Health and Skin in Obese Males N/A
Completed NCT02737592 - A Clinical Study to Evaluate the Safety of a Personal Lubricant in Healthy Female Subjects N/A
Completed NCT03852563 - A Study to Gain Information How Well Dexpanthenol Derma Cream Helps the Face Skin to Recover After Cosmetic Lasering N/A
Completed NCT05300542 - Efficacy Study of a Novel Skin Health Product to Reduce an UVB Induced Erythema N/A
Completed NCT03477825 - Pilot Study of Triphala and Rubia Cordifolia on Gut Microbiome and Skin N/A
Completed NCT02490943 - A Pilot Study of Warm and Cold Compress to Reduce Injection Site Erythema Due to Peginterferon-beta-1a in MS N/A